sibenadet has been researched along with Airflow Obstruction, Chronic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alcaraz, L; Bailey, A; Cadogan, E; Connolly, S; Dainty, I; Jewell, R; Jordan, S; Kindon, N; Lawson, M; Lister, A; Mullen, A; Nicholls, D; Paine, S; Pairaudeau, G; Stocks, MJ; Thorne, P; Young, A | 1 |
| Rennard, SI | 1 |
| Dougall, IG; Ince, F; Jackson, DM; Young, A | 1 |
| Deamer, L; Ind, PW; Laitinen, L; Laursen, L; Nystrom, P; Wenzel, S; Wouters, E | 1 |
| Hepburn, T; Laursen, LC; Lindqvist, A; Lloyd, J; Perrett, J; Rocchiccioli, K; Sanders, N | 1 |
| Byrne, N; Celli, B; Goldman, M; Halpin, D; Hepburn, R; Keating, ET | 1 |
| Alderfer, V; Goldman, M; Hiller, FC | 1 |
| Jones, MK; Lordan, N; McMillan, C; O'Brien, JA; Ward, AJ | 1 |
| Jones, MK; Leidy, NK; Lloyd, J; Rocchiccioli, K; Schmier, JK | 1 |
| Calverley, P; Casty, F; Goldman, M; Keating, ET | 1 |
| Agnew, JE; Dilworth, JP; Hasani, A; Lloyd, J; Toms, N | 1 |
7 trial(s) available for sibenadet and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Thiazoles; Treatment Outcome; Vital Capacity | 2003 |
The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Metered Dose Inhalers; Middle Aged; Patient Satisfaction; Peak Expiratory Flow Rate; Pulmonary Disease, Chronic Obstructive; Quality of Life; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Thiazoles; Treatment Outcome | 2003 |
Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Cough; Double-Blind Method; Dyspnea; Female; Forced Expiratory Volume; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Sputum; Survival Analysis; Thiazoles; Treatment Outcome; Vital Capacity | 2003 |
Long-term use of Viozan (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Long-Term Care; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Smoking; Thiazoles; Treatment Outcome | 2003 |
Utilization of health care services by patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Double-Blind Method; Female; Health Services; Hospitalization; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Pulmonary Disease, Chronic Obstructive; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Thiazoles | 2003 |
Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale.
Topics: Adrenergic beta-Antagonists; Aged; Bronchodilator Agents; Cough; Data Collection; Dopamine Antagonists; Dyspnea; Female; Health Status Indicators; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Sensitivity and Specificity; Sputum; Thiazoles | 2003 |
Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Mucociliary Clearance; Peak Expiratory Flow Rate; Pulmonary Disease, Chronic Obstructive; Quality of Life; Risk Factors; Smoking; Sputum; Thiazoles; Treatment Outcome; Vital Capacity | 2005 |
4 other study(ies) available for sibenadet and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.
Topics: Adrenergic beta-Agonists; Animals; Asthma; Bronchodilator Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Cyclic AMP; Drug Design; Guinea Pigs; Humans; Inhibitory Concentration 50; Models, Chemical; Protein Binding; Pulmonary Disease, Chronic Obstructive; Thiazoles; Time Factors | 2012 |
Introduction. The symposium that never occurred: pre-clinical and clinical development of sibenadet.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Dopamine Antagonists; Humans; Pulmonary Disease, Chronic Obstructive; Thiazoles; Treatment Outcome | 2003 |
Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; Drug Design; Humans; Models, Biological; Neurons, Afferent; Pulmonary Disease, Chronic Obstructive; Receptors, Dopamine D2; Thiazoles | 2003 |
Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Cough; Drug Design; Dyspnea; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Research Design; Sputum; Thiazoles | 2003 |